Available for Licensing

Used upon waking, this new medical device (Biosymtec Monitor™) will be able to noninvasively detect developing respiratory and non-respiratory infections up to two days before symptoms, permitting early medical intervention.

Available for Licensing

The Biosymtec Monitor will provide an immediate report to the user or caretaker and a 50-day graph of readings on mobile devices using Predictive's patented graph template.

Available for Licensing

The Biosymtec Monitor advanced model will read T, PEF, FEV1, FVC, HR, SpO2, eO2, eNO, EKG and BGL.   You will be able to scroll through the readings and forward them with the touch of a button.   Algorithmic infection alerting will be done with color backlighting.

Research Studies

Studies conducted in Hong Kong, Tianjin* and Pennsylvania produced very encouraging results, using Predictive's proprietary algorithm.

Sensitivity 96.7%
Selectivity 96.8%

*Tianjin Haihe Hospital

Predictive Inc.
Research Team

The Research Team, seeking pre-symptomatic signs of infection, focused its efforts on the large COPD, asthma and CHF patient-population markets.

Biochemist, Joseph Johnson
                        Corporate officer
Research Engineer, John Beiswenger
                        President & CEO
Medical Doctor, James Wilson

Patented technology

Predictive Inc. and SMT Manufacturing Group will design, prototype and produce this new concept in medical devices, for the Licensee, through pilot production to be used in clinical and/or market research studies.


To communicate with
John Beiswenger, President and CEO of Predictive Inc., please use the form on the right or send an email to jbeiswenger@predictiveincorporated.com.

Click on above for details.